Dr. Reddy’s Laboratories has launched Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets in the U.S. market.Sensipar is a trademark of Amgen Inc. The drug is indicated for Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis.The Sensipar brand and generic market had U.S. sales of around $312 million MAT for the most recent twelve months ending in July 2020, a release from Dr. Reddy’s said citing IQVIA Health numbers.The Hyderabad-headquartered drugmaker said the launch follows U.S. Food and Drug Administration (USFDA) approval for the product. Dr. Reddy’s Cinacalcet Tablets are available in 30 mg, 60 mg and 90 mg strength in a bottle count size of 30, the release said.
A letter from the Editor
Dear reader,We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
Support Quality Journalism
A letter from the Editor
Dear subscriber,Thank you!Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.Suresh Nambath
